Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A…
These are university-run results at high dose — do they hold at the doses and settings a company would actually market?
Reasonable evidence with real limitations. how we score evidence
Caveat on this rating: Small N, discriminable drug (unblinding likely), academic two-center trial; independent of MindMed/Definium, which is a strength.
Two positive phase 3 toplines in 2026 (MDD, GAD) — press-release-stage, not peer reviewed or FDA reviewed. Breakthrough Therapy designation Mar 2024 (GAD).
In 42 patients with anxiety (with or without life-threatening illness), two 200-µg LSD sessions reduced STAI-Global anxiety 16 weeks later by 16.2 points more than placebo (d=1.18), with one serious adverse event (acute transient anxiety); crossover carryover forced reliance on first-period comparisons, shrinking the effective sample.
Worth asking
These are university-run results at high dose — do they hold at the doses and settings a company would actually market?
Source
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study — Holze F, et al. (2023)
Reputable peer-reviewed journal
Read the source: https://doi.org/10.1016/j.biopsych.2022.08.025
DOI: 10.1016/j.biopsych.2022.08.025
How this was scored
- Study design
- Randomised controlled trial
- Funding
- Funding not disclosed
- Published in
- Reputable peer-reviewed journal
- Sample size
- 42
- Preregistered
- Yes
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "moderate evidence". Reasonable evidence with real limitations. It scores 63 out of 100 on our published rubric. One caveat travels with that badge: Small N, discriminable drug (unblinding likely), academic two-center trial; independent of MindMed/Definium, which is a strength. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study — Holze F, et al. (2023). Published in: Reputable peer-reviewed journal. DOI: 10.1016/j.biopsych.2022.08.025. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Randomised controlled trial. Funding: Funding not disclosed. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is lsd, lysergide FDA approved for this use?
No. Its current status is: Phase 3 trials. Two positive phase 3 toplines in 2026 (MDD, GAD) — press-release-stage, not peer reviewed or FDA reviewed. Breakthrough Therapy designation Mar 2024 (GAD).
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.